TAMPA, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Memgen, Inc., a clinical-stage biotechnology company developing oncolytic immunotherapy for solid tumors, today announced the dosing of the first patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results